Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is a leading cause of nosocomial infection. 1 Vancomycin is usually used to treat MRSA infections, but high-level vancomycin-resistant S. aureus (VRSA) has emerged mainly due to the acquisition of the vanA operon from Enterococci. 2 There are also VRSA isolates with lower levels of vancomycin resistance, including vancomycin-intermediate S. aureus (VISA) and heterogeneous VISA (hVISA). 3 The causes for the different levels of vancomycin resistance in MRSA are not completely clear.
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Lin et al Previous studies on hVISA and VISA strains have revealed 60 genes that may be associated with vancomycin resistance. 4, 9, 10, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] We hypothesized that some nucleotide sequence variations in these genes correlate with the difference in vancomycin susceptibility of VSSA and VISA isolates. To test this hypothesis, we investigated the prevalence of SNVs of these 60 genes and found 29 SNVs (in 12 genes) that were more common in hVISA and VISA than in VSSA isolates. Among them, three novel amino acid sequence variations including Q692E in FmtC, T287I in HtrA and K101E in Upps proteins were found to be significantly associated with vancomycin resistance.
Materials and methods
Bacteria strains and growth conditions
In total, 87 MRSA isolates were used in this study, including 72 from Chang Gung Memorial Hospital, 3 from National Taiwan University Hospital, 8 from Tri-Service General hospital (TSGH) and 2 each from Chi Mei Medical Center and China Medical University Hospital. These isolates were collected from 2009 to 2014. Detailed information of these isolates is presented in Table 1 . All isolates were stored at −80°C and grown on tryptic soy agar plates at 37°C for 16 hours for the studies.
Whole-genome sequencing and polymerase chain reaction (PCR)
The whole genome of two VISA isolates (TSGH205 and TSGH243) was sequenced. Genomic DNA of each isolate was isolated and sonicated to generate fragments of 300-500 bp for construction of a DNA library, which was then subjected to Illumina next-generation sequencing. Raw sequence data generated were filtered and assembled for analysis using the CLC Genomics Workbench (QIAGEN, Venlo, the Netherlands). Genes selected for investigation of vancomycin resistance and PCR primers used to amplify these genes are shown in Table 2 . PCRs were performed in a buffer containing 10 mM Tris-HCl (pH 8.0), 1.5 mM MgCl 2 and 50 mM KCl under the following conditions: 5 minutes at 95°C, followed by 35 cycles of 30 seconds at 95°C for denaturation, 30 seconds at 55°C for primer annealing and 1 minute at 72°C for extension, and 5 minutes at 72°C for final extension. PCR products were verified by sequencing.
Minimum inhibition concentration (MIC) E-tests
E-test was performed to determine the vancomycin MIC of VSSA, hVISA and VISA isolates. Cells of an overnight culture of each isolate were suspended in 0.9% NaCl solution, adjusted to 0.5 McFarland unit and spread evenly on a Mueller-Hinton agar plate. An E-test strip (bioMérieux, Durham, NC, USA) was placed on the agar plate, which was then incubated at 35°C overnight to determine MIC values.
Population analysis profile/area under the curve PAP/AUC was performed to identify hVISA and VISA isolates as previously described. 24, 25 Briefly, serial dilutions of the overnight culture of an isolate were plated on brain heart infusion agar plates containing different concentrations of vancomycin (0, 0.5, 1, 1.5, 2, 3, 4, 6 and 8 μg/mL). After incubation at 35°C for 48 hours, colony-forming units (CFUs) of the isolate were determined and graphed as log 10 CFU/ mL value versus vancomycin concentration to calculate the AUC. Reference strains Mu3 and Mu50 were analyzed in an identical manner to serve as hVISA and VISA controls, respectively. To distinguish VSSA, hVISA and VISA, the ratio (PAP/AUC value) of the AUC of an isolate to the AUC of Mu3 was calculated. The following ratios were used for 
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SNVs associated with vancomycin resistance in VISA identification of VSSA, hVISA and VISA populations: VSSA, <0.9; hVISA, 0.9-1.3; VISA, >1.3.
Results
Nucleotide sequence variations in genes related to vancomycin resistance
The 87 MRSA isolates used in this study included 30 VSSA, 41 hVISA and 16 VISA isolates (Table 1) . To test the hypothesis that some SNVs in the previously identified 60 genes (Table S1 ) correlate with the difference in vancomycin susceptibility of VSSA and VISA isolates, the nucleotide sequences of these 60 genes in these MRSA isolates were examined. To simplify the bioinformatics work, this examination was performed in a stepwise manner to gradually narrow down the scope of analysis. Genes with SNVs were first identified, followed by determination of the prevalence of the SNVs in the MRSA isolates, identification of novel SNVs and then correlation of these novel SNVs with vancomycin resistance.
For the first step of analysis, the sequences of the 60 genes in two each of VSSA (N315 and JH1) and VISA (TSGH205 and TSGH243) isolates were aligned and compared. These four strains were selected because their entire genome had been sequenced. The two VSSA strains (N315 and JH1) were found to differ in nucleotide sequences in 13 genes, whereas the two VISA strains (TSGH205 and TSGH243) differed in nucleotide sequences in 25 genes, indicating that genes in the VISA isolates are more variable. Most of these sequence variations are SNVs. After excluding SNVs that were common in the two VSSA and two VISA strains, 29 SNVs in the following 12 genes were found in both VISA strains (TSGH205 and TSGH243): fmtC, graR, graS, htrA, mecA, pbp2, pbp4, srtA, tcaA, upps, vraR and vicK (Table 3 ). These genes have been shown to be related to the two-component system (graR, graS, vicK and vraR), cell membrane synthesis (tcaA), cell wall synthesis (mecA, pbp2, pbp4 and srtA) or vancomycin resistance (htrA, fmtC and upps).
10,11
Prevalence of the 29 SNVs in VSSA, hVISA and VISA isolates
In the second step of analysis, the association of these 29 SNVs with vancomycin resistance was determined. To achieve the goal, the nucleotide sequences of the aforementioned 12 genes of 16 additional clinical isolates were compared, including five VSSA, nine hVIS and two VISA strains. Results showed that two VSSA, five hVISA and all VISA isolates had the same 29 SNVs. Six of these SNVs were novel and resulted in the following amino acid changes: Q692E in FmtC; T278I, P306L and I311T in HtrA; and I63V and K101E in Upps (Table 4) .
Amino acid sequence variations in HtrA, FmtC and Upps associated with vancomycin resistance
In the third step of analysis, the role of these six novel SNVs in vancomycin resistance was then investigated by detecting their presence in 69 additional MRSA isolates. These isolates included 25 
Discussion
Previous studies have revealed 60 genes that may be related to vancomycin resistance, 6, 9 suggesting that vancomycin resistance is a complex phenomenon and is mediated not by a single gene but by a group of genes. Among these 60 genes, 41 were found to be associated with vancomycin resistance by expression analysis; 10, 14, 16, [20] [21] [22] [23] 8 were found by overexpression, deletion or insertion mutations; 10, 15, 18, 19 11 were found by analysis of SNVs. 4, 9, 11, 17, 20 In this study, we found 29 SNVs in the following 12 genes: fmtC, graR, graS, htrA, mecA, pbp2, pbp4, srtA, tcaA, upps, vraR and vicK (Table 3) . Six of these 29 SNVs in fmtC, htrA and upps are novel. Since we only examined the sequences of these 12 genes in a limited number (87) of MRSA isolates, it is conceivable that other isolates may have other important sequence variations that were not detected in this study.
Of the 12 genes with SNVs, graR, graS, vicK and vraR are related to the two-component system. 9 The others (mecA, pbp2, pbp4, srtA, tcaA, fmtC, htrA and upps) are more closely associated with vancomycin resistance. The mecA gene encodes the penicillin-binding protein 2a (PBP2a), which plays a role in resistance to beta-lactam antibiotics. Previous studies have shown that vancomycin treatment triggers deletions in the mecA gene. 26, 27 The N146K, N204K and G246E mutations in the MecA protein that we found in this study are located near or in the dimerization domain of PBP2a (KEGG database; http://www.kegg.jp/ssdb-bin/ ssdb_motif?kid=sav:SAV0041) and would cause conformational changes of PBP2a. A recent study showed that these mutations (N146K, N204K and G246E) are highly associated with ceftaroline resistance, 28 suggesting that they are also related to vancomycin susceptibility.
The pbp2 and pbp4 genes encode other penicillin-binding proteins (PBPs), which are also major components of the cell wall. The N-terminal domain of these PBPs encodes a glycosyltransferase, which catalyzes glycan chain polymerization from lipid II. Their C-terminal domain encodes a transpeptidase, which cross-links glycan chains. 29 In addition 
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SNVs associated with vancomycin resistance in VISA to the glycosyltransferase and transpeptidase domains, PBP4 also has a domain encoding a carboxypeptidase, which hydrolyzes the C-terminal d-Ala-D-Ala peptide bond of the precursor of peptidoglycan. 30 Previous studies have shown that vancomycin treatment increases the expression of pbp2, but decreases the expression of pbp4 in S. aureus. 31 It has been shown that pbp4 mutations result in a decrease in its carboxypeptidase activity, leading to increased production of D-Ala-D-Ala termini in peptidoglycan and decreased vancomycin-binding affinity. 31 The sequence variation S189T in PBP4, we found in this study, is located in its carboxypeptidase domain (KEGG database; http://www.kegg.jp/ ssdb-bin/ssdb_motif?kid=sav:SAV0642) and conceivably would reduce its activity.
Previous studies on PBP2 have found that mutations in the transpeptidase domain of PBP2 increase the susceptibility of S. aureus to ceftizoxime. 32 The C197Y, A420V and A557T mutations in PBP2 found in this study are located in its transpeptidase and transglycosylase domains (KEGG database; http://www.kegg.jp/ssdb-bin/ssdb_motif?kid=sav:SAV1450). The C197Y mutation has been shown to be associated with the susceptibility of S. aureus to ceftaroline, 33 which is effective for treatment of hVISA or VISA infections. 34 Although the other two mutations have not been investigated, it is conceivable that they will alter the activity of PBP2.
The srtA gene encodes sortase A, which is involved in the modification of cell surface proteins. 35 Transcriptome analysis revealed a decreased expression of srtA by vancomycin 
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Lin et al treatment. 10 The N167K mutation identified in this study is located in the sortase domain (KEGG database; http://www. kegg.jp/ssdb-bin/ssdb_motif?kid=sav:SAV2528) and, thus, would decrease its activity.
The tcaA gene encodes a membrane protein that has been shown to be associated with glycopeptide resistance. 36 Structural analysis showed that amino acid residues 195-322 of the TcaA protein contain an OprB porin domain (http://www.kegg.jp/ssdb-bin/ssdb_motif?kid =sauf:X998_2340) of the ABC transporter, which plays a major role in carbohydrate uptake. Previous studies have shown that the ABC transporter is also involved in bacterial multidrug resistance. 37 Since the five amino acid variations (L218P, Y237H, T262S, R283H and G312D) in the TcaA protein we found are all located in its OprB porin domain, it is conceivable that these mutations will affect vancomycin resistance. 
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SNVs associated with vancomycin resistance in VISA In this study, six novel SNVs were found in fmtC, htrA and upps genes that have not been shown to be associated with vancomycin resistance. Three of them (Q692E in FmtC, T287I in HtrA and K101E in Upps) were correlated with vancomycin resistance (Tables 5-7 ). The htrA gene encodes a serine protease of the DegP family. 38 Previous studies have shown that HtrA can suppress the production and secretion of bacteriocin by Streptococcus pneumonia. 39 Bacteriocinproducing enterococci and staphylococci also have been described. [40] [41] [42] There have been no reports on the relationship between bacteriocin production and vancomycin resistance. Bacteriocin production has been shown to augment niche competition by enterococci in the gastrointestinal tract. 43 It is unknown whether any of the MRSA isolates examined in this study produces bacteriocin. Therefore, the mechanisms by which HtrA mediates vancomycin resistance remain to be investigated. The T278I mutation is predicted to be located in the coil structure of HtrA (http://www.ebi.ac.uk/interpro/ protein/Q5HH63). It is possible that this mutation alters the secondary structure and thus the enzymatic activity of HtrA, leading to vancomycin resistance.
The upps gene encodes undecaprenyl pyrophosphate synthase, which catalyzes the formation of undecaprenyl pyrophosphate (UPP) by condensing farnesyl pyrophosphate with eight molecules of isopentenyl pyrophosphate. 44 UPP is a lipid carrier during peptidoglycan synthesis. Inhibition of Upps has been shown to suppress cell wall synthesis and decrease the susceptibility of bacteria to vancomycin. 11 Structural prediction (EMBL-EBL; http://www.ebi.ac.uk/ interpro/protein/A0A1D4QTF1) revealed that Upps has a dimer interface residue at amino acid position 101. Thus, the K101E variation discovered in this study very likely would destabilize Upps, leading to vancomycin resistance.
The fmtC (also called mprF) gene encodes phosphatidylglycerol lysyltransferase that mediates lysinylation of phosphatidylglycerol. 45 Mutations in fmtC in S. aureus and Bacillus subtilis have been shown to cause a decrease in the production of lysyl-peptidoglycan, thus increasing negative charges of the cell membrane and reducing the susceptibility of bacteria to vancomycin and daptomycin. 46, 47 The Q692E mutation, that we found in this study, is located in the IPR02430 domain (EMBL-EBL; http://www.ebi.ac.uk/ interpro/entry/IPR024320), which is involved in the transfer of the lysyl group from l-lysyl-tRNA to membrane-bound peptidoglycan. This mutation very likely will disrupt this process, resulting in vancomycin resistance.
Limitations of this study include limited number of MRSA isolates examined and lack of detailed information of infections caused by the isolates, correlation between gene expression levels and vancomycin resistance, and functional studies of the SNVs. Therefore, the possibility that the SNVs discovered in this study may not completely correlate with vancomycin resistance of MRSA isolates still exists.
Conclusion
We have identified 29 SNVs that are more prevalent in hVISA and VISA than in VSSA isolates. Through sequence comparison of 87 isolates, we demonstrated that three novel SNVs in htrA, upps and fmtC genes are associated with vancomycin resistance. Since other environmental factors such as coinfections and patient's conditions may also affect vancomycin resistance, allelic replacement or complementation of these SNVs needs to be performed to confirm the roles of these mutations in vancomycin resistance.
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